# Prior Authorization Policies for Pediatric ADHD Medication Prescriptions

Form Approved OMB No. 0920-0879 Expiration Date 03/31/2018

#### Instructions

Welcome! This information collection is meant for state Medicaid Medical Directors, or their designee, with knowledge of state Medicaid policies related to pediatric attention-deficit/hyperactivity disorder (ADHD) treatment. The Policy Surveillance Program at Temple University Beasley School of Law (PSP) and the Centers for Disease Control and Prevention (CDC) have already begun collecting information about your state's Medicaid policies from publicly available sources. The purpose of this questionnaire is to verify that we collected the most up-to-date and accurate information from your state.

Your feedback is important to us. Your participation will help us identify where and why there are gaps in Medicaid reimbursement related to ADHD treatment, which will allow us to conduct more precise analyses on the impacts of these policies.

Completing the questionnaire is voluntary and takes approximately 20 minutes. Please note that any personally identifiable information about respondents related to their official duties (name, position, agency, phone, and email) will be removed when the results of this questionnaire are aggregated for analysis. Responses will be kept secure and will not be shared with other respondents or other entities. There are no known risks or direct benefits to you from participating or choosing not to participate, but your answers will help CDC improve its understanding of Medicaid policies that influence pediatric ADHD treatment and might help other states develop or improve their policies.

If you have any questions or concerns about this assessment, please email the CDC at ADHDpolicy@cdc.gov.

To begin, please proceed to page 2 of this instrument.

When you have completed this survey, please click the SUBMIT button on page 1 or email as an attachment to ADHDpolicy@cdc.gov.

CDC estimates the average public reporting burden for this collection of information as 20 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-0879).

#### Section A.

The Temple PSP and CDC have compiled information on ADHD prior authorization policies across all states and the District of Columbia. For the purposes of responding to all questions below, a prior-authorization policy is defined as any policy that requires prior authorization, additional review, or other additional prescriber involvement for obtaining approval and payment for ADHD medications prescribed to children younger than age 18 years.

The policy information we have compiled should reflect what was accurate for your jurisdiction as of November 1, 2015.

1. Please review Appendix A to verify the prior authorization policy information we collected for your state. Is the information listed in Appendix A the most up-to-date policy in your state?

Yes

No, we have updated our policy since November 1, 2015

No, we did not have a policy on November 1, 2015, but we now have a policy

No, the policy you have provided is incorrect

Other

If your state Medicaid program does NOT currently have any prior-authorization policy limiting ADHD medication prescriptions to children younger than age 18 years, PLEASE SKIP AHEAD TO SECTION B.

If you answered "No" to question 1, please email a copy of the most recent version of your state's policy to <a href="mailto:ADHDpolicy@cdc.gov">ADHDpolicy@cdc.gov</a>, and include the policy's effective date.

2. Please review Appendix B to verify the table listing characteristics of your state's policy. Are all of the responses correct as of November 1, 2015?

Yes

No, at least one response is not correct as of November 1, 2015

Unsure whether all responses are correct as of November 1, 2015

If you answered "Yes" to question 2, please skip question 3 and continue to question 4.

Please indicate below which questions you believe we did not correctly answer in Appendix B. Then, ease add an explanation in the box to the right.		
Questions from Appendix B:		
Does your state Medicaid program have a policy that requires prior authorization for ADHD medications prescribed to children younger than age 18 years?	The answer to this question in Appendix B is not correct.	
Please explain.		
Which ages require prior authorization?  Please explain.	The answer to this question in Appendix B is not correct.	
Does the policy automatically deny authorization for certain ages?  Please explain.	The answer to this question in Appendix B is not correct.	
Does the policy specify ADHD medications that require prior authorization?  Please explain.	The answer to this question in Appendix B is not correct.	
Are stimulants included?  Please explain.	The answer to this question in Appendix B is not correct.	

Question from Appendix B (continued): Reminder: If you answered "Yes" to que	estion 2, please skip q	uestion 3 and continue to question 4.
Are non-stimulants included?		The answer to this question in Appendix B is not correct.
	Please explain.	
Does the policy list criteria for approval	?	The answer to this question in Appendix B is not correct.
	Please explain.	
What criteria are listed to receive appro	val? Please explain.	The answer to this question in Appendix B is not correct.
4. How is the prior-authorization app	roval process trigge	red in your state?
At the medication's point-of-sale		
When the prescriber submits a prior	r-authorization form to	a reviewing body
Other (please explain)		
5. Is the prior-authorization request p	peer-reviewed by me	dical experts?
Yes		
No		
Don't know		
Other (please explain)		
6. When was the very first prior authors 18 years old? (Please indicate "unsu		emented in your state for children younger that

	Yes
	No
	Don't know
lf	yes, please explain below.
Se	ection B.
	ease answer the following additional questions regarding <b>behavioral health carve-outs</b> for services provided children (< age 18 years) in your state Medicaid program.
	Does your state Medicaid program currently carve out behavioral or mental health services provided to children?
	Yes
	No
	Don't know
lf y	you answered "No" to question 8, please skip to question 11.
	If your Medicaid program currently carves out any behavioral or mental health services for children, which ervices are carved out?
	Outpatient behavioral/mental health services
	Inpatient behavioral/mental health services
	Prescription drugs
	Substance abuse services
	Other (please explain)
10	. How are they carved out?
	Carved out to a fee-for-service delivery system
	Carved out to a behavioral health organization
	Other (please explain)

7. Has your program ever evaluated this prior authorization policy's effect on prescription rates?

health services in the pa	ist five years.		
	Not Carved Out	Carved Out	Unsure
2015			
2014			
2013			
2012			
2011			
2010			
Please contact CDC with any	questions, or to discuss your sta	te's Medicaid program in gr	reater detail.
Contact Information		, , ,	
	wing information about the per	son who completed this s	survey:
First Name:	_	Last Name:	•
Job Title:		Description of your position	:
State:		Department:	
E-mail:		Phone:	
14. Has this survey been de	elegated to you by the Medicaid	Director or Medicaid Med	dical Director in
Yes			
No			
Don't know			

11. Please complete the following matrix to indicate if your state has ever carved out children's behavioral



#### **APPENDIX A**

#### **Click here** to return to question 1.

# Prior Authorization Guidelines ADHD Medications in Children Under 6 Years Old

## **FDA Approved Indication**:

Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

## **Guidelines for Approval:**

- 1. The requesting clinician has documented that the child has a diagnosis of ADHD
- 2. Psychosocial issues and non-medical interventions are being addressed by the clinical team.
- 3. Documentation of psychosocial evaluation occurring before request for ADHD medications.
- 4. Documentation of non-medication alternatives that have been attempted before request for ADHD medications.

## **Additional Requirements:**

Children under 6 years old will be monitored in accordance with the ADHS/DBHS Clinical Practice Protocol on Psychiatric Best Practice Guidelines for Children: Birth to Five Years of Age.

# **Coverage is Not Authorized for:**

- 1. Indications other than ADHD.
- 2. Doses greater than FDA recommended maximum daily dosage.

#### References:

- 1. ADHS/DBHS: Provider Manual Section 3.15: Psychotropic Medication: Prescribing and Monitoring
- 2. Manufacturer Product Information
- 3. Pliska SR, Greenhill LL, Crismon ML, et al. The Texas children's medication algorithm project: report of the Texas census conference panel on medication treatment of childhood deficit/ hyperactivity disorder. Part 1. J Am Academy Child Adolescent Psychology. 200;39(7):920-927

Finalized 8/5/2013

# **APPENDIX B**

**Click here** to return to question 2.

**Click here** to return to question 3.

08/05/2013 - 11/01/2015	◆ View Law	
5	Vac	
Does the state Medicaid program have a policy that requires prior	Yes	
authorization for ADHD medications prescribed to children younger than age 18 years?	§	
→ Which ages require prior authorization?	Child younger	
	than 1	
	1 year old	
	2 years old	
	3 years old	
	4 years old	
	5 years old	
	9	
→ Does the policy expressly deny authorization for certain ages?	No	
Does the policy specify ADHD medications that require prior authorization?	No	
Does the policy list criteria for approval?	Yes	
	9	
➤ What criteria are listed to receive approval?	ADHD diagnosis	
	Psychological	
	evaluation	
	Consideration of non-medication	
	alternatives	
	§	